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Abstract
The peptide hormone somatostatin (SST) and its five G protein-coupled receptors (SSTR1-5) were described to be present in
the skin, but their cutaneous function(s) and skin-specific signalling mechanisms are widely unknown. By using receptor
specific agonists we show here that the SSTRs expressed in keratinocytes are functionally coupled to the inhibition of
adenylate cyclase. In addition, treatment with SSTR4 and SSTR5/1 specific agonists significantly influences the MAP kinase
signalling pathway. As epidermal hormone receptors in general are known to regulate re-epithelialization following skin
injury, we investigated the effect of SST on cell counts and migration of human keratinocytes. Our results demonstrate a
significant inhibition of cell migration and reduction of cell counts by SST. We do not observe an effect on apoptosis and
necrosis. Analysis of signalling pathways showed that somatostatin inhibits cell migration independent of its effect on
cAMP. Migrating keratinocytes treated with SST show altered cytoskeleton dynamics with delayed lamellipodia formation.
Furthermore, the activity of the small GTPase Rac1 is diminished, providing evidence for the control of the actin
cytoskeleton by somatostatin receptors in keratinocytes. While activation of all receptors leads to redundant effects on cell
migration, only treatment with a SSTR5/1 specific agonist resulted in decreased cell counts. In accordance with reduced cell
counts and impaired migration we observe delayed re-epithelialization in an ex vivo wound healing model. Consequently,
our experiments suggest SST as a negative regulator of epidermal wound healing.
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Introduction
Proliferation and migration of cells play pivotal roles in wound
healing as well as in tumorigenesis. During wound closure, the
activation and termination of wound healing processes must be
tightly regulated to prevent pathological wound responses.
Therefore, it is important to identify the signals that direct these
cellular processes and elucidate their mechanisms.
Re-epithelialization, which is necessary for wound closure and
restoration of barrier function after skin injury, requires directional
keratinocyte migration from the wound edges as well as cell
proliferation at the wound margins [1,2]. Both, proliferation and
migration of keratinocytes, are controlled by extracellular
hormones, providing attractive opportunities for therapeutic
intervention [3,4,5].
Somatostatin (SST) is a regulatory peptide hormone of 14
amino acids with a wide expression in a variety of tissues [6]. It
acts through five different G-protein coupled receptors (SSTR1-5),
all of which couple to inhibitory G-proteins of the Gai/o-type.
Consequently, many SSTR expressing cells respond to SST
treatment by a reduction in cAMP (cyclic adenosine monophos-
phate) levels [7]. SSTR activation also modulates the MAP
(mitogen-activated protein) kinase pathway which is known to
have an influence on cell proliferation [8,9]. In addition, SSTRs
hyperpolarize excitable cells through the activation of potassium
channels [10] and the inhibition of voltage-gated calcium channels
[11]. As has been observed for other G protein-coupled receptors
[12], interactions with additional intracellular signalling molecules
(e.g. PDZ domain-containing adaptor proteins) modify the
subcellular localization and the signalling capabilities of SSTRs
[13,14,15]. Thus, dependent on the cellular context, SSTRs may
not only inhibit the release of neurotransmitters and hormones,
but also affect cell proliferation, migration, or the formation of
cellular junctions.
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11We and others have recently provided evidence that SST and its
receptors are present in human skin and cultured keratinocytes
[14,16,17,18]. SST is mainly found in dendritic cells and Merkel
cells [16,18,19]. The localization of the five SSTR subtypes was
shown in all living layers of the human epidermis by immunohis-
tochemistry with heterogeneous staining intensity and also
differences in subcellular localization [17,18]. Furthermore, in
comparison to healthy skin, Hagstro ¨mer et al. detected an
increased immunoreactivity for SSTR4 and SSTR5 in psoriatic
epidermis [17]. However, the functional relevance of the various
SSTRs and the underlying signalling mechanisms in human
keratinocytes are largely unknown except for the involvement of
SSTR3 in tight junction composition and function [18].
As endogenous SST agonists (SST14, SST28 and cortistatin) act
on all SSTR subtypes with similar efficiency, it has been initially
difficult to assign specific functions to receptor subtypes. This has
been improved with the advent of specific agonists [20], allowing
to dissect the role of individual subtypes more clearly.
Here, we present a systematic functional analysis of the SST/
SSTR system in human keratinocytes. Our data confirm on the
mRNA level that all five SSTR subtypes are expressed in human
skin. In addition, we show for the first time that SST, by inhibiting
the activity of Rac1 and influencing lamellipodia formation, is a
powerful regulator of keratinocyte migration. Further, we show an
inhibitory effect of SST on cell counts independent from apoptosis
and necrosis and its influence on the MAP kinase pathway in
primary keratinocytes. Our data indicate that these cellular
processes might result in an inhibition of wound healing by SST
which is consequently shown here for the first time in a porcine ex-
vivo wound healing model.
Results
Expression of all SSTR subtypes in human skin and
keratinocytes
For a comprehensive analysis of the SSTR system in human
skin, we analyzed samples from human skin by RT-PCR using
primers specific for the various SSTR subtypes. mRNAs coding
for all five receptor subtypes were detected (Fig. 1A), consistent
with the immunohistological observations of a previous report
[17]. All five mRNAs were also readily detected in cultured human
keratinocytes obtained from neonatal foreskin samples (Fig. 1B). In
addition, all receptor mRNAs could be detected in commercially
available epidermal skin equivalents (see Fig. 1B for SSTR5 as an
example).
Activation of SSTR subtypes results in adenylate cyclase
inhibition
A characteristic feature of SSTRs is to couple to inhibitory
G-proteins and therefore to reduce cellular cAMP levels [21].
To clarify whether SSTR subtypes are functionally expressed in
human keratinocytes we investigated the effect of SST on
cellular cAMP content (after induction of cAMP production by
the treatment of cells with forskolin, FSK). Somatostatin elicited
a dose dependent decrease in FSK-stimulated cAMP levels,
with an IC50 of 32 nM (+/25 nM) (Fig. 1C) which is in
agreement with previously published dose response data [10].
Importantly, SST does not affect basal cAMP levels in
keratinocytes [18]. Whereas SST is a non-selective agonist for
all SSTR subtypes, several subtype specific agonists have been
described [20], which were used here to discriminate between
the individual subtypes. All specific agonists that were available
to us (sst2, sst3, sst4, sst5/1) elicited a decrease in FSK induced
cAMP levels, indicating that SSTR2, SSTR3, SSTR4 and
either one or both of SSTR1 and SSTR5 - as the corr-
esponding agonist activates both receptors - are coupled to
adenylate cyclase inhibition in human keratinocytes, demon-
strating their functionality (Fig. 1D).
SSTR4 and 5/1 activation modulates MAP kinase activity
To further elucidate somatostatin signaling in keratinocytes,
we analyzed the coupling of SSTRs to the activation of MAP
kinases. Keratinocytes were treated with SST, fetal calf serum,
or a combination of both, and analyzed for the activating ERK
(extracellular signal-regulated kinase) phosphorylation using a
phospho-ERK1/2 specific antibody. Stimulation with FCS was
used as a positive control, as serum growth factors are known to
effectively activate ERKs via receptor tyrosine kinases [22,23].
Here, SST stimulated ERK phosphorylation almost as strongly
as FCS, and the combination of FCS and SST led to a further
increase in ERK activity (Fig. 2A, B). MAP kinase activation
is transient as we observed a prominent phosphorylation 5 min
after treatment which was less pronounced after 10 min
(Fig. 2A).
By using the subtype specific agonists, the increase in ERK
activity can be largely assigned to the action of the SSTR4.
Interestingly, the SSTR5/1 specific compound inhibited ERK
activation, demonstrating subtype selective activation or inhibition
of MAP kinases (Fig. 2C).
Taken together, these data indicate that all SSTR subtypes are
expressed in human keratinocytes, and that all of them are
functionally coupled to inhibition of adenylate cyclase activity
while only SSTR4 (activating) and SSTR5/1 (inactivating) are
involved in MAPK signalling. This prompted us to investigate
whether SSTRs affect pivotal functions of keratinocytes i.e.
proliferation and migration and whether we can find receptor
subtype specific differences.
Cell counts are reduced by activation of SSTR5/1
Treatment of actively proliferating keratinocytes with SST
resulted in a marked reduction of cell counts 72 hours after
application (reduction to 75% compared to non-treated cells,
Fig. 3A). Simultaneously, SST treatment had no effect on
apoptosis and necrosis (Fig. 3C, D). When we repeated the cell
growth experiments using the receptor subtype specific agonists,
only the SSTR5/1 specific compound elicited a similar reduction
in cell counts. This was consistent with its inhibitory effect on ERK
activation (see above). SSTR2, 3 and 4 specific agonists did not
show a significant effect (Fig. 3B).
SST influences keratinocyte migration via all receptor
subtypes
Cell migration assays were performed with confluent monolay-
ers of human keratinocytes, which were mechanically scratched
and subsequently allowed to re-populate the cell-free wounded
areas. Cells were pre-exposed to irradiation to exclude any effects
of proliferation. While in assays using control keratinocytes the
scratched area was closed within 18 h (Fig. 4A), application of SST
resulted in a significant delay of scratch area closure, consistent
with decreased cell migration (Fig. 4A, B). In contrast to cell
counts, which were significantly affected only by the SSTR5/1
specific agonist, migration of keratinocytes was decreased by all
four different subtype specific compounds (Fig. 4C). Because we
did not observe a significantly higher level of inhibition of
migration with somatostatin which activates all five SSTRs
compared to the various agonists, a distinct cumulative effect of
the agonists is unlikely (Fig. 4B, C).
Somatostatin Inhibits Wound Healing
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To elucidate the putative mechanisms for decreased keratino-
cyte migration after SST application, we first asked whether this
effect might be mediated by the cAMP regulation through SST.
Therefore, we investigated the influence of forskolin on keratino-
cyte migration in combination with or without SST. As all five
receptor-selective agonists showed redundant anti-migratory
effects, we concentrated on the inhibitory effect of the endogenous
agonist SST. We observed that the up-regulation of cAMP by
forskolin also resulted in a significant inhibition of migration
(Fig. 5). This inhibition was even more pronounced than the
inhibition obtained by treatment with SST. Combination of SST
and forskolin did not enhance the effect of FSK alone. These
results strongly suggest that inhibition of migration by SST is not
mediated by cAMP.
SST inhibits lysophosphatidic acid (LPA) induced
migration of keratinocytes
Lysophosphatidic acid (LPA), which acts through a different
family of G protein-coupled receptors is a stimulator of
keratinocyte migration [24]. Therefore we investigated whether
Figure 1. SSTR subtypes are expressed in human skin and are functionally coupled to the cAMP pathway in primary keratinocytes.
mRNA isolated from normal human skin (A) and primary human keratinocytes (B) was analyzed for the presence of mRNAs coding for the five
somatostatin receptor subtypes SSTR1-5 by RT-PCR using subtype specific primer combinations. In (B) an example for SSTR-expression in epidermal
skin equivalents (SSTR5) and in rat brain (SSTR2; positive control) is shown additionally. C: Inhibition of cAMP signalling by increasing concentrations
of SST in forskolin-stimulated keratinocytes. Keratinocytes were stimulated with 10 mM forskolin for 10 min without SST (100% cAMP synthesis) or
with 10–1000 nM SST. Results are shown as means+/2SD. Data were fitted by non-linear regression using GraphPad Prism software; the calculated
IC50 value for SST is 32+/25 nM. D: Effect of different SST receptor agonists on cAMP levels after stimulation of cAMP synthesis by forskolin (FSK,
means+/2SEM, * P,0.05, *** P,0.005.). 1 mM SST as well as selective receptor agonists (sst2-sst5/1 at a concentration of 1 mM) inhibited cAMP
synthesis, showing that all receptor subtypes couple to cAMP signalling pathways.
doi:10.1371/journal.pone.0019740.g001
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significantly reduces the LPA-induced migration of keratinocytes
(Fig. 5), hinting at a common signalling pathway.
Decreased migration is associated with reduced
lamellipodia formation
To further investigate which signalling mechanisms in this
pathway might mediate this alteration of cell migration, we
concentrated on the F-actin based cytoskeleton which is essential
for cell motility [25] and which has been shown to be influenced
by LPA [26]. In untreated scratched cell monolayers we observed
numerous F-actin-rich lamellipodia which extended towards the
scratched area. Treatment with SST significantly reduced the area
covered by these lamellipodia (Fig. 6). On the other hand,
treatment of keratinocytes with LPA results in an increase in
lamellipodial area. This increase could be blocked by simultaneous
application of SST, clearly demonstrating that SST inhibits
lamellipodia formation in migrating keratinocytes.
SST reduces the amount of active Rac1 during cell
migration
Re-arrangements of the actin cytoskeleton have been shown to
be mediated by Rho GTPases [27], and formation of lamellipodia
in particular by the activity of Rac1 [28,29]. We therefore
investigated whether SST interferes with Rac1 activity during the
migration process. Non-proliferating keratinocyte monolayers
were again scratched and subsequently treated with or without
SST. The active, GTP-bound form of Rac1 was then precipitated
from cell lysates using a GST fusion of the Rac binding domain of
the typical Rac effector PAK1. We observed a significant
reduction in the amount of active Rac1 protein when cells had
been treated with SST compared to controls (Fig. 7). Thus, our
data demonstrate that activation of SSTRs in keratinocytes leads
to an inhibition of Rac1 activity, which is likely to be the cause for
the limited lamellipodia formation and cell migration.
SST delays epidermal re-epithelialization in an ex vivo
wound healing model
As both keratinocyte proliferation and migration were inhibited
by SSTR activation, we next determined effects of SST on
epidermal re-epithelialization in a porcine ex vivo wound healing
model. We compared wound closure in untreated and SST-
treated wound models 48 h post-wounding and observed that
epidermal wound closure is delayed in SST-treated models
(Fig. 8A). Quantitative evaluation of the healing rates shows that
re-epithelialization is significantly reduced in the presence of SST
(Fig. 8B).
Discussion
In agreement with previous studies from our and other
laboratories, our data firmly establish the presence of the
somatostatin receptor system in human skin and in cultured
human keratinocytes. Besides supporting on a molecular level the
findings of Hagstro ¨mer et al. [17], who have shown the presence of
all five SSTR subtypes by immunohistochemistry, we now present
for the first time evidence that all of them are functionally coupled
to effector proteins such as the adenylate cyclase and – for some
subtypes - MAP kinases.
It was shown before that the ligand somatostatin itself is
expressed in the epidermis primarily in Merkel cells as well as in
dendritic cells [16,18,19]. In addition, it was demonstrated that
nerve fibres in the skin are positive for somatostatin [30]. Senapati
et al. [31] determined the concentration of somatostatin in rat skin
to be 1–3 nM, i.e. in the range of Kd-values reported for SSTR1-
5. Local concentrations at secretion sites may be even higher.
These findings prompted us to ask to what extent SST
contributes to the regulation of important epidermal functions,
i.e. the cell growth and migration of keratinocytes which are
essential elements of the wound healing process but also for
tumorigenesis.
Cell counts are specifically reduced by the application of SST
and the SSTR5/1 specific agonist. Because we did not see an
influence of SST on apoptosis and necrosis we assume that
reduced cell counts origin in a reduced cell proliferation. However,
we can not exclude a further effect on cellular senescence.
Interestingly, SSTR5/1 is the very agonist which was able to
reduce the amount of the activated form of ERK. A negative
influence on cell proliferation is a common characteristic of SST,
which has been demonstrated e.g. in different carcinoma cell lines
[32,33], but has never been shown for keratinocytes. As the agonist
used activates both SSTR1 and 5 we were not able to distinguish
between these two receptors, but the effect is likely to be mediated
Figure 2. SSTR activation in keratinocytes modulates the MAP
kinase pathway. A: MAP kinase activity assay. Cells were treated with
1 mM SST or 5% FCS (or both) for 5 or 10 min and lysates were analyzed
with antibodies against ERK1/2 or phospho-ERK1/2 by Western blotting.
B: The relative intensities (control value=1) of 6 experiments after
5 min treatment were quantified and are shown as means +/2 SEM
(* P,0.05, *** P,0.005.). C: Effect of different SST receptor agonists on
ERK phosphorylation (n=5; * P,0.05, ** P,0.01), a representative blot
is shown below. SST as well as the SSTR4-specific agonist significantly
induces ERK phosphorylation, while treatment with agonist sst5/1
results in significantly decreased phospho-ERK levels.
doi:10.1371/journal.pone.0019740.g002
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via MAP kinases [34]. The fact that the SSTR2 specific agonist does
not elicit inhibition of cell growth may seem surprising, giving the
large body of literature linking this receptor to antiproliferative
signalling (e.g. [33]). However, it should be noted that such effects
were observed mostly in tumor cells which overexpress the SSTR2.
In keratinocytes, the SSTR2 is likely to be expressed at physiological
levels, which may not be sufficient to inhibit proliferation. Of note,
Haegerstrand et al. [35] did not observe an influence of 0.1 mM
somatostatinoncellcountofprimarykeratinocytes.However,thecell
culture conditions used in their experiments were completely different
tooursandincludedmousefeedercells,BSAandhighconcentrations
of EGF which might influence the results. In addition, the
discrepancy could originate in different concentrations of somato-
statin as we used 1 mM.
In addition to the effects on cell growth we could show for the
first time an inhibition of cell migration by SST in human
keratinocytes. Of note, in contrast to the restricted influence of
SST on cell counts only via SSTR5/1, migration is inhibited by
the activation of all receptor subtypes, indicating a redundancy of
the receptors for this function. Our data suggest that inhibition of
cell migration by somatostatin is a common cellular feature, as it
was also found in cells of neuronal origin [36,37]: Consistent with
our observations, Pola and colleagues observed that all subtype
selective SSTR agonists significantly reduced cell migration in
neuroblastoma cells [37]. The redundancy of SSTR subtypes for
migration in different cellular systems might reflect their
importance for this cellular process. We assume that the specific
complement of receptor subtypes expressed in keratinocytes
enables the cell to shape a specific response e.g. in the wound
healing process. Thus either SSTR1 or SSTR5 will be necessary to
inhibit proliferation, while the other subtypes may also contribute
to the regulation of migration.
Even though all receptor subtypes lead to a decrease of
forskolin-stimulated cAMP levels and to a decrease in migration,
our experiments using forskolin to increase cellular cAMP levels
show that the influence of SST on migration is independent from
its effect on cAMP. As already described by McCawley et al [38],
elevation of cAMP levels by forskolin efficiently reduces cell
migration. This reduction was not affected by simultanous
treatment with SST. Our data fit well with findings of Chen
et al., (2002) who described that activation of the b2-adrenergic
receptor inhibits keratinocyte migration via a cAMP-independent
mechanism [39]. The b2-adrenergic receptor is positively coupled
to cAMP generation via the stimulatory G-protein Gas [4] and
Chen et al. proposed that the decrease of migration is mediated by
inhibition of MAP kinase signalling. However, even though we
have shown here that the MAPK pathway is influenced by SST, it
is unlikely that this is the cause for the decrease of migration
observed in our studies. Migration is inhibited by all 5 receptors of
SST while ERK activation is only inhibited by SSTR1/5 and even
increased by SSTR4.
Figure 3. Somatostatin receptor activation reduces keratinocyte cell counts but does not influence apoptosis and necrosis. A: Cells
were stimulated with 1 mM SST for 72 h and the effect on cell counts was evaluated. Results are percentages compared to untreated cells (n=13). B:
Effect of selective SSTR agonists on cell counts (n=4). Only the SSTR5/1-specific agonist inhibits keratinocyte proliferation. C: Effect of 1 mM SST on
apoptosis. D: Effect of 1 mM SST on necrosis (positive controls for C and D as included in the assays; positive controls=100%; n=3). Results are shown
as means+/2SEM, *** P,0.005.
doi:10.1371/journal.pone.0019740.g003
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lamellipodia formation through modulation of Rho GTPase
signalling. This could either be achieved through an inhibition
of Rho-family-specific guanine nucleotide exchange factors
(RhoGEFs) or an activation of GTPase activating proteins
(RhoGAPs). Members of both protein families have been
described to be activated by subunits of the heterotrimeric G-
proteins (e.g. [40,41]) and in some cases interact directly with
receptors via C-terminal PDZ domain binding motifs [42].
Interestingly, such motifs are also present in SSTRs [14]. We
observed a decreased activation of Rac1 by SST; this Rho GTPase
has been shown to be involved in directed migration and
reorganization of the cellular actin cytoskeleton [27]. Interestingly,
Tscharntke and colleagues [43] showed that Rac1 deletion in
primary keratinocytes or transgenic mice leads to reduced cell
migration and re-epithelialization. Furthermore, deletion of Rac1
in fibroblasts inhibits wound healing in vivo [44]. The induction of
lamellipodia formation by the phospholipid LPA is also dependent
on Rac1 activation [29]. In the presence of SST, we observed a
reduction in LPA-induced lamellipodia formation in human
keratinocytes. Therefore, we suggest that SST influences Rac1
activation and reorganization of the cytoskeleton. However, one
has to keep in mind that LPA can bind to several receptors and
can influence besides Rac1 also cAMP levels, ERK, phospholipase
C and intracellular Ca
2+. Furthermore it can also result in gap
junction closure and tight junction (TJ) opening [45,46].
Consequently, we can not exclude that SST might also be
involved in additional signalling pathways. Of note, we have
previously shown that SST can increase TJ barrier function via the
human SSTR3 [18,47].
As keratinocyte proliferation and migration are essential
processes in wound healing, we investigated the influence of SST
on re-epithelialization in an ex vivo wound healing model. In
accordance with the decrease in proliferation and migration in
cultured keratinocytes we observed a delay of re-epithelialization in
our wound healing model. Interestingly, Waddell et al., described a
negative influence of the therapeutic SSTR agonist octreotide
(SandostatinH) on wound breaking strength in rat skin [48]. The
authors attribute this effect to an inhibition of trophic hormones
following a 7-day subcutanous injection of octreotide. In contrast,
we could show a local action of SST in epidermal wound healing
and propose a direct effect of SST on epidermal keratinocytes.
While the effects of activating signals (e.g. growth factors) on
wound healing are well studied, the influence of negative
regulators is largely unknown [2,49]. However, after induction
by positive regulators it is important to control the fundamental
changes in human keratinocyte activity by limiting factors (such as
somatostatin). These regulators are required to self-limit the
wound repair process to ensure an orchestrated closure of the
wound. Of note, there is growing evidence that wounding
promotes epidermal tumorigenesis [50,51] and several authors
have hypothesized that ‘‘cancer is an overhealing wound’’ (for
review see [52]) which also points to a role of SST agonists in the
therapy of skin cancer. An interesting question is how somatostatin
and SSTR expression changes during wound regeneration. A
decrease in epidermal concentrations of SST has been reported
during early phases of wound healing in rat skin [31]. The authors
do not discuss the relevance of this depletion, but it is conceivable
that this decrease allows efficient keratinocyte migration and
proliferation during wound repair. To this end, it would be
interesting to test whether somatostatin levels do increase in later
stages of the wound healing process. Therefore, in future
experiments it will be of great interest to investigate how SSTR
and SST expression is regulated in normal human wound healing
and chronic wounds and also to specifically elucidate the potential
of SSTR antagonists in these wounds.
In conclusion, our data show for the first time receptor subtype-
specific signal transduction pathways of SST in human keratino-
cytes and its influence on migration and cell counts and,
consequently, re-epithelialization of cutaneous wounds.
Materials and Methods
Antibodies, cDNAs, primers and reagents
Rabbit anti-ERK (#9102) and mouse anti-phospho-ERK
(#9106) were purchased from Cell Signaling (Danvers, USA),
fluorophor-labelled phalloidin (#MFP-A2283) was from Mobitec
(Go ¨ttingen, Germany) and mouse anti-Rac1 (#610650) from BD
Biosciences (San Jose, USA). Somatostatin was purchased from
Bachem (Weil am Rhein, Germany, #H-1490), Forskolin (FSK,
#F6886) and lysophosphatidic acid (LPA, #L7260) were from
Sigma. Whole skin and brain cDNA was purchased from
Invitrogen (Karlsruhe, Germany). Subtype specific SSTR agonists
(sst2: L-779,976, sst3: L-796,778, sst4: L-803,087 and sst5/1: L-
Figure 4. Activation of SST receptors results in the inhibition of
keratinocyte migration. A: Keratinocyte monolayers were scratch
wounded and the scratched area was examined directly after scratching
(0 h) and every 6 hours during an incubation period of 24 h. To prevent
proliferative effects, cells were pre-exposed to X-ray irradiation to
induce cell cycle arrest. B: Quantification of cell migration in scratch
assays after SST stimulation (1 mM SST for 24 h). Data are presented as
percentages of the recovered scratch area relative to untreated control
cells (n=7). C: Effect of selective SSTR agonists (1 mM for 24 h) on cell
migration compared to untreated cells (n=5). All subtype-specific
agonists tested inhibit keratinocyte migration. Results are shown as
means+/2SEM, * P,0.05, ** P,0.01, *** P,0.005.
doi:10.1371/journal.pone.0019740.g004
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(1 mM), FSK (10 mM) or LPA (5 mM) as well as combinations of these substances. Data are presented as percentages of the recovered scratch area
relative to untreated control cells (n=5) Results are shown as means+/2SEM, * P,0.05, compared to controls; * P,0.05 between different treatment
groups.
doi:10.1371/journal.pone.0019740.g005
Figure 6. SST delays lamellipodium formation in the early phase of keratinocyte migration. A: Lamellipodium formation in migrating
keratinocytes. Cells were scratch wounded, treated as indicated, fixed after 3 h of migration and the actin cytoskeleton was visualized with
fluorophor-labelled phalloidin. Lamellipodia are marked by an overlay of red pseudocolor. B: Areas of extending lamellipodia were measured after 3 h
for each treatment and compared to control cells (n=3, total number of analyzed cells is indicated inside bars, means+/2SEM, * P,0.05).
doi:10.1371/journal.pone.0019740.g006
Somatostatin Inhibits Wound Healing
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(Rahway, New Jersey). The binding affinities of somatostatin
and the SSTR agonists are: Somatostatin: 0.5–1.6 nM for SSTR1-
5; sst2: 0.05 nM for SSTR2; sst3: 24 nM for SSTR3; sst4: 0.7 nM
for SSTR4; sst5/1: 0.4 nM for SSTR5, 3.3 nM for SSTR1
[20,53]. Values were determined in receptor-overexpressing cell
lines and due to lower efficacies in primary cells, concentrations in
micro-molar range were chosen for experiments. The receptor-
specific agonists exhibit 100-fold to 10,000-fold selectivity against
the other SSTR subtypes. SSTR subtype specific primers (SSTR1:
Hs00265617_s1, SSTR2: Hs00265624_s1, SSTR3: Hs00265
633_s1, SSTR4: Hs01566620_s1, SSTR5: Hs00265647_s1) were
purchased from Applied Biosystems (Darmstadt, Germany).
Cell culture
Normal human skin used for the cultivation of primary
keratinocytes was obtained during the routine clinical removal of
neonatal foreskin. Their usage was approved by the local medical
ethics committee (060900). Isolated cells were cultured in
keratinocyte growth medium (KGM; Medium 154, Cascade
Biologics, Karlsruhe, Germany) supplemented with 0.07 mM
Ca
2+ using a modified protocol of Rheinwald and Green [54].
Determination of cell counts
For the determination of cell counts, keratinocytes were seeded
in 6 well plates (density: 50,000 cells/well) and treated with 1 mM
SST or selective SSTR agonists for 72 h. Cells were trypsinized
and cell numbers were determined by using a hemocytometer.
Determination of apoptosis and necrosis
For determination of cell death, keratinocytes were seeded into
24-well plates at a density of 650,000 cells/well and treated with
1 mM SST for 72 hours. Afterwards, apoptosis was measured by
applying the Cell Death Detection ELISA kit (Roche, Mannheim,
Germany) and necrosis by applying the Cytotoxicity Detection
ELISA kit (Roche, Mannheim, Germany).
Cell scratch assay
For in vitro migration assays, keratinocytes were seeded in
Collagen I-coated wells at a density of 100,000 cells/well. After
reaching confluency, cells were irradiated for 20 min with
200 keV (0.8 Gy/min) to induce cell cycle arrest. The cell
monolayer was wounded using a sterile pipette tip and washed
twice with PBS to remove cell debris. Then, KGM with 1 mM
SST, 1 mM selective SSTR agonists, 10 mM FSK or 5 mM LPA
was added. The wound area was photographed with phase
contrast at marked positions (3 different fields per well in
triplicate). Cells were allowed to migrate for 12 and 24 h at
37uC and the same fields were photographed again. Scratched
areas were measured with ImageJ software (NIH, Bethesda, USA)
and recovered surface area over 12 and 24 h was calculated
compared to untreated cells.
Measurement of lamellipodium areas
Measurement of lamellipodium areas was done by immunoflu-
orescent visualization of actin-rich cell protrusions. Keratinocytes
were grown on coverslips to confluency and scratch wounded as
described above. Cells were treated with either 1 mM SST, 5 mM
LPA or both. After 3 h of migration, cells were fixed (4%
formaldehyde in PBS) and permeabilized (0.1% Triton X-100 in
PBS). After blocking (3% BSA), cells were incubated with
fluorophor-labelled phalloidin and counterstained with DAPI.
After mounting, the actin cytoskeleton was visualized with an
Axiovert 135 epifluorescence microscope (Zeiss, Go ¨ttingen,
Germany) and the area of lamellipodia extending into the wound
surface was measured with ImageJ software.
RNA isolation and RT-PCR
Total RNA from keratinocytes was isolated using Tri reagent
(Sigma) and a subsequent purification using RNeasy columns
(Qiagen, Hilden, Germany). cDNA was generated with iScript
cDNA synthesis kit (Bio-Rad, Munich, Germany) and PCR was
performed as described [55]. Preparations of RNA template
without reverse transcriptase were used as negative controls.
Cyclic AMP assay
Cells were seeded in 96-well dishes at a density of 25,000 cells/
well.Beforestimulation,cellswerepreincubatedfor30 minwiththe
phosphodiesterase inhibitor isobutylmethylxanthine (500 mMi n
KGM) to prevent cAMP degradation. The cells were incubated for
10 min with 10 mM forskolin in the absence or presence of different
concentrations of somatostatin. Intracellular cyclic AMP levels were
determined using the HitHunter cAMP XS+ kit according to the
manufacturer’s instructions (GE Healthcare, Munich, Germany).
Figure 7. SST decreases Rac1 activity in migrating keratinocytes. A: The amount of active Rac1 was determined by affinity precipitation with
purified GST-PAK[PBD]-fusion protein from keratinocyte lysates 3 h after induction of migration. SST treatment reduces active Rac1 compared to
untreated cells. Precipitation with GST alone was used as negative control. (I) input, (P) precipitate. B: Relative quantification of Rac1 activity
(control=100%; n=4). Results are shown as means+/2SEM, ** P,0.01.
doi:10.1371/journal.pone.0019740.g007
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Primary keratinocytes were stimulated with 1 mM SST, 5%
FCS or both and incubated for 5 and 10 minutes at 37uC. After
washing with PBS, cells were lyzed with lysis buffer (50 mM Tris/
HCl; pH 8.0, 150 mM NaCl, 1% (v/v) NP-40, 0.5% (w/v) Na-
deoxycholate, 5 mM EDTA, 0.1% SDS). Lysates were cleared by
centrifugation and subjected to SDS-PAGE. Amounts of total
and active ERK (extracellular signal-regulated kinase)/MAP
kinase were determined with ERK1/2 and phospho-ERK1/2
antibodies by Western blotting. Quantifications of signal inten-
sities were done with a ChemiDoc XRS imager and Quantity
One software (Bio-Rad).
Active Rac1 precipitation assay
Active (GTP-bound) Rac1 was precipitated from keratinocyte
lysates with an immobilized glutathione-S-transferase (GST) fusion
protein of the purified Rac1 binding domain of the p21 activated
kinase PAK1(PAK[PBD]; [56]). The GST-PAK fusion protein
was expressed and isolated from E. coli and bound to glutathione
sepharose (GE Healthcare); GST alone was used as a control.
Confluent primary keratinocytes were extensively scratched so that
a large percentage of cells was localized at wound edges, and lyzed
after 3 hours of migration with lysis buffer. Lysates were cleared by
centrifugation and GST-PAK-beads were added to cleared lysates
and incubated for 1 h at 4uC on a rotator. The beads were washed
three times with lysis buffer and bound proteins were separated by
12% SDS-PAGE. GST-PAK bound (active) and total cellular
Rac1 were detected by Western blotting using a monoclonal
antibody specific for Rac1 (BD Biosciences). Signal intensities were
quantified with a ChemiDoc XRS imager and Quantity One
software (Bio-Rad).
Ex vivo wound healing models
Punch biopsies with a diameter of 6 mm were taken from
porcine ear skin. Subsequently another 3 mm punch biopsy
including epidermis and the upper dermis was excised, resulting in
a central wound. The biopsies were placed dermis down on gauze
in culture dishes filled with Dulbecco’s modified Eagle’s medium
supplemented with 2% fetal calf serum, hydrocortisone, penicillin
and streptomycin. The resulting models were incubated at air-
liquid interface at 37uC with the application of 5 ml PBS or SST
(2 mM) into the central wound directly and 24 h after wounding.
After 48 hours, the samples were snap-frozen in isopentane
precooled with liquid nitrogen and stored at 280uC. Re-
epithelialization was evaluated in hematoxylin and eosin-stained
cryostat sections by measuring the length of regenerated epidermis
with an axiophot II microscope and openlab software 2.0.9
(Improvision, Coventry, UK) light microscopy [57,58].
Statistical analysis
Data are presented as mean values 6 standard deviation or 6
standard error of mean (see figure legends). Data sets were checked
for normal distribution (Shapiro-Wilk test) and equal variance.
When possible, p-values were determined by Student’s t-test.
Otherwise (MAPK-Phosphorylation, Proliferation with Agonists,
Rac-Pulldown), Mann-Whitney U test was performed. Differences
were considered statistically significant with a p-value less than
0.05.
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